These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

616 related items for PubMed ID: 9007121

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.
    Rowinsky EK, Flood WA, Sartorius SE, Bowling MK, Wagner J, Ettinger DS.
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):48-54. PubMed ID: 7644928
    [Abstract] [Full Text] [Related]

  • 29. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer.
    Natale RB.
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):51-4. PubMed ID: 9007122
    [Abstract] [Full Text] [Related]

  • 30. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer.
    Chang AY, Boros L, Asbury R, Hui L, Rubins J.
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-69-S17-71. PubMed ID: 9374098
    [Abstract] [Full Text] [Related]

  • 31. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L, Jovtis SL, Mickiewicz E, Temperley G, Rondinón M, Blajman C, Cóppola FS, Lewi D, Cazap E, Breier S, Fasce H, Fein L, Polera J, Triguboff E, Uranga G, Pasccón G, Luchina AM, Martínez CA, Politi PM, Rubio G, Alvarez AM.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study.
    Bunn PA, Kelly KL.
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):54-8; discussion 59-60. PubMed ID: 7481862
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
    Paul DM, Garrett AM, Meshad M, DeVore RD, Porter LL, Johnson DH.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer.
    Rosell R, Felip E, Massuti B, González-Larriba JL, Benito D, López-Cabrerizo MP, Salamanca O, Camps C, Puerto-Pica J.
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-56-S12-60. PubMed ID: 9331123
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.